HOO-IMM PLUS-B - Treatment in India
ANTI HBV DRUG
HOO-IMM PLUS-B An Anti-Viral Treatment For Acute And Chronic HBV Infected Patients
HOO-IMM PLUS-B, A Herbal Composite Formula Ensures Effective Action On Multiple Targets Simultaneously Anti-HBV, Anti-Hepatocellular Carcinoma (HCC) And Hepatoprotective.
- ACTIVE MOLECULES AND ACTION.
- HBV DNA QUANTITATIVE.
- NORMAL LIVER FUNCTION.
- Other ARVs TREATMENT.
- PREVENTING VIRAL INDUCED CARCINOMA.
- NOT ONLY VIRAL SUPPRESSION BUT ERADICATION.
HOO-IMM PLUS-B an anti-viral treatment for acute and chronic HBV infected patients primarily focus on the viral entry inhibition also inhibit DNA Polymerase of HBV virus in combination with other multi target against HBV which could block re-infection and protect hepatocyte those are healthy liver cells opening a new natural therapeutic options without any means of side effects for HBV infected individuals.
Hepatitis B Virus infection is the major health problem throughout the world affecting more than 350 million people who are carriers of this virus that can cause chronic hepatitis, liver cirrhosis and hepato cellular carcinoma.
HOO-IMM PLUS, a herbal composite formula ensures effective action on multiple targets simultaneously anti-HBV, anti-Hepatocellular Carcinoma (HCC) and Hepatoprotective.
The anti-HBV activity of HOO-IMM PLUS has been reported by many Ayush clinicians in India and pharmacist from Africa. HOO-IMM PLUS has been extensively clinically studied against HBV on the inhibition of HBsAg secretion PLC/PRF/5 Cells and also the inhibition of Hepato carcinoma in HepG2 cell line. Clinically patients receiving Hooimm plus reported Target not detected in HBV DNA Quantitative.
ANTI-HEPATOCELLULAR CARCINOMA (HCC)
The HOO-IMM PLUS-B constitute curcumin molecule which has been proven a star key molecule in preventing hepatocellular carcinoma. Many research have been done on curcumin suggesting that it inhibits proliferation induces apoptosis, potentiate attenuate ROS. But the poor systemic absorption of curcumin is major obstacle for its efficacy. Here we have a unique extraction procedure for curcuma longa which yields curcumin with high degree bioavailaibility and along with other herbal extract formulation that improves the gut absorption of curcumin.
Hoo-imm Plus-B prevents liver injury from viral hepatitis. HBV individuals receiving Hoo-imm plus treatment having normalized liver enzyme. The treatment prognosis reports normal level of the routine test of Serum Alanine Aminotransferase (ALT) or Serum glutamic pyruvic transaminase (SGPT) and Aspartate Aminotransferase (AST). AST and SGPT is a blood test that checks for the liver damage. SGPT and AST levels in the blood rise if your liver is damaged.
Biomarker or Test protocol involved in the anti-hbv treatment with Hooimm plus:-
1. HBV Serological markers which include HBsAg & HBeAg Elisa.
2. Serum Alanine Aminotransferase (ALT) or Serum glutamic pyruvic transaminase (SGPT) & Aspartate Aminotransferase (AST) or SGOT.
3. HBV DNA Quantification-Viral Load.
Note: Quantification of HBV DNA reflects the viral load which plays a critical role in determining the phase of infection, deciding the treatment and determining the response to anti-viral treatment. This test is highly recommended in Chronic HBV- World Health Organization (WHO)
HOO-IMM Plus-B is a novel herbal formulation for the treatment of HIV & HBV infections manufactured by HOOTONE REMEDIES. It�s in the capsule formation consisting of 750 mg extract of 10 different plant species
Each 750 mg contains:-
|1||Muleti Ext||Glycyrrhiza glabra||75 mg|
|2||Bhui Amlaki Ext||Phyllanthus Niruri||75 mg|
|3||Larry the Bird||Terminalia Chebula||75 mg|
|4||Bhojpatra Ext||Betula Utilis||75 mg|
|5||Punnaga Ext||Callophyllum Inophyllum||75 mg|
|6||Haldi Ext||Curcuma Longa||75 mg|
|7||Nirgundi Ext||Justica Gendarussa||75 mg|
|8||Kalmegh Ext||Andrographis Paniculata||75 mg|
|9||Karela Beej Ext||Memordica Charantia||75 mg|
|10||Bichu Buti Ext||Urtica dioica||75 mg|
HOO-IMM PLUS polyherbal formulation consists of number active molecules of different plant species act on multiple targets against HBV.
Glycyrrhiza Glabra :
Glycyrrhizin, a major component of a herb (licorice), has been widely used to treat chronic hepatitis B in Japan. This substance improves liver function with occasional complete recovery from hepatitis Its effects on the secretion of hepatitis B surface antigen (HBsAg) were examined in vitro. Glycyrrhizin suppressed the secretion of HBsAg and accumulated it dose-dependently in PLC/PRF/5 cells.
Phyllanthus Niruri :
An aqueous extract of the plant Phyllanthus niruri inhibits endogenous DNA polymerase of hepatitis B virus and binds to the surface antigen of hepatitis B virus in vitro. Phyllanthus significantly reduced serum HBV DNA (a marker of efficacy) as well as HBeAg (a marker of viral replication). A potential anti-HBV agent, ellagic acid, was isolated from the medicinal plant P. niruri, and its physicochemical properties were characterized. Phyllanthus niruri (Bhumyamalaki) had ability to inhibit HBV polymerase to decrease episomal HBV DNA content by downregulating HBV messenger RNA transcription.
Terminalia Chebula :
Studied and found that 90% of Terminalia chebula ethanolic extracts inhibited on HBs antigen binding assay and HBV DNA polymerase inhibition assay. In silico analysis of potent compounds from Terminalia chebula proved to be effective against Hepatitis B virus. In HBs antigen binding assay, the lyophilized ethanolic extracts of Terminalia chebula exhibited 60% of maximum inhibition whereas the aqueous extracts showed 55% of inhibition and the control lamivudine exhibited 60% of inhibition.
Cucurma Longa :
Curcumin treatment led to time- and dose-dependent reductions in HBsAg and HBeAg expression and significant reductions in intracellular HBV DNA replication
Andrographis Panicula :
Dehydroandrographolide and andrographolide, two natural diterpenoids isolated from Andrographis paniculata possessed activity against HBV DNA replication
Failed HBV Treatment :
Several anti-viral those are currently available for the treatment of HBV which includes IFN alpha, Lamuvidine, Entecavir, Telbibudine and Tenofovir.
Interferon therapy has limited efficacy, slow acting and frequently causes adverse effect. Undesirable side effects of interferon treatment are found such as fever, malaise, fatigue, depression, hair loss, neutropenia and thrombocytopenia.
On the other hand the side effects of Tenofovir is no less than Interferon. The common side effects includes fever, pain, diarrhea, vomiting, depressed mood, rashes, insomnia. Moreover, the anti-viral drug and Interferon are expensive. Moreover, if the patient drops the Tenofovir medication even for 48 hours the HBV viral load elevates to 1000 copies/ml.
Why HBV treatment is highly recommended?
HBV infection leads to severe diseases, including hepatitis, liver cirrhosis and hepatocellular carcinoma.
HBV has also been suggested to be involved in the development of pancreatic cancer. Approximately 4 crore individuals are infected with HBV, and more than 1.5 lakh people with HBV infection die every year as a result of end-stage liver disease and hepatocellular carcinoma in India.
Most of the mortality due to Viral Hepatitis is attributed to Hepatitis B and C, which are also known as silent killers as more than 80% of the infected aren�t aware of their infection.
Hepatitis B and C infections can remain asymptomatic for years, even decades, slowly damaging the liver.
Fighting hepatitis is difficult because both hepatitis B and C are chronic infections that often remain dormant in the body for years before damaging the liver. Liver cirrhosis and liver cancer are common culminations of these chronic infections. Most people infected with the virus are not aware about their disease status.
Chronic HBV infection accounts for 40-50% of hepatocellular carcinoma (HCC) and 20-30% cases of liver cirrhosis while chronic HCV infection accounts for 12- 32% of HCC and 12-20% of liver cirrhosis in the country.